Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. Lawsuit - VERV
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. Lawsuit - VERV
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VERV
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ:VERV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Stockholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / October 18, 2024 / If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ:VERV) and reminds investors of the October 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
